David A Ramsay
CIK 1283292 · EVP, PRESIDENT, DRUG DELIVERY · last filed 2026-07-02
David A Ramsay is an EVP, PRESIDENT, DRUG DELIVERY who has filed 78 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for HALO, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$4.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $12.7M across reported positions. 11 SEC filings were submitted jointly with LA JOLLA PHARMACEUTICAL CO.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SVRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
11588 SORRENTO VALLEY ROAD, #17
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HALO | EVP, PRESIDENT, DRUG DELIVERY | 4,592 | $103.63 | $475.9K | $0 | 1 | 2026-07-02 |
| HTI | Interim CFO | 364,320 | — | — | -$33.8K | 19 | 2026-04-02 |
| SVRA | Director | 2,533,642 | $4.83 | $12.24M | $3.85M | 39 | 2025-12-19 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Director | 97,000 | $6.22 | $603.3K | $384.8K | 9 | 2022-01-14 |
| MSTX | Director | — | $11.85 | — | $0 | 4 | 2017-01-23 |
| Savara Inc (ANX) Delisted | Director | 100,000 | — | — | $55.1K | 4 | 2012-07-30 |
Recent Filings
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | HALO | Mixed | +4,592 | -$423.3K | EDGAR |
| 2026-04-02 | HTI | Grant (A) | — | $0 | EDGAR |
| 2025-12-19 | SVRA | Sell (S) | −20,000 | -$121.2K | EDGAR |
| 2025-12-18 | SVRA | Notice (144) | −20,000 | -$122.2K | EDGAR |
| 2025-12-11 | SVRA | Grant (A) | +40,000 | $0 | EDGAR |
| 2025-04-01 | SVRA | Buy (P) | +150,000 | $416.2K | EDGAR |
| 2024-12-16 | SVRA | Grant (A) | +40,000 | $0 | EDGAR |
| 2024-11-18 | SVRA | Buy (P) | +100,000 | $287.6K | EDGAR |
| 2023-12-15 | SVRA | Grant (A) | +22,500 | $0 | EDGAR |
| 2023-05-26 | SVRA | Buy (P) | +100,000 | $258.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.